GRAPEFRUIT USA INC - GPFT STOCK NEWS

Grapefruit USA (GPFT) has signed a term sheet with Al Habtoor Group to finance its 2-acre development in Desert Hot Springs, California. This project is part of the company's growth strategy as it transitions from a traditional cannabis entity to a canna-biotech firm. The company has secured a permit for a 30,000-square-foot facility that will feature an indoor grow operation and a licensed distribution hub. Due diligence is now underway, with final financing details to be announced after completion.

Grapefruit USA, a California-based cannabiotech company, responds to the NFL's recent $1 million research grant aimed at studying cannabinoids for pain management and concussion prevention in athletes. Two research teams, from the University of San Diego and the University of Regina, will explore these effects. CEO Bradley Yourist emphasizes Grapefruit's Hourglass THC/CBD and hemp-based CBD-infused topical creams as effective alternatives to smoking or oral ingestion. These products align with the NFL's initiative to harness cannabinoids in sports medicine.

Grapefruit USA, Inc. (OTCQB: GPFT) has filed a Notice of New Cannabis Product (NNCP) with Health Canada, a critical step towards selling its Hourglass™ Time Release THC+CBD-Infused Topical Delivery Cream in Canada. The approval will allow Grapefruit to enter the largest federally legal cannabis market worldwide. CEO Bradley J. Yourist emphasized the NNCP filing as a pivotal event in the company's history. This follows Canada's federal legalization of cannabis in 2018, establishing a structured framework for cannabis product regulation and sales.

Grapefruit USA (OTCQB: GPFT) has announced that its distribution partner, Medz Cannabis, filed a Notice of New Cannabis Product with Health Canada. This approval is crucial for Grapefruit to sell its patented Hourglass™ Time Release THC+CBD-Infused Topical Delivery Cream in Canada. The product aims to provide safe cannabinoid ingestion without the health risks associated with smoking or oral methods. CEO Bradley Yourist expressed confidence in the Canadian market's acceptance of the Hourglass cream, set for launch in 2022.

Grapefruit USA, Inc. (OTCQB: GPFT) is set to advance its operations in the cannabis sector, filing for a Notice of New Cannabis Product with Health Canada for its Hourglass THC+CBD-infused cream. Sales are expected to launch by Q1 2022 through Medz Cannabis, Inc. The company is also developing a 30,000 sq. ft. facility in California, with three financing offers under consideration. Additionally, a clinical study on the cream's effects on rheumatoid arthritis is planned, alongside resumed talks for a potential joint venture in Canada.

Grapefruit USA, Inc. (OTCQB: GPFT) has announced that its patented Hourglass™ time-release THC+Cannabinoid delivery cream is now available for delivery through Blitzdirect.com in California. This partnership allows Grapefruit to reach customers who may be unable to visit retail locations, enhancing accessibility for users. The effectiveness of the Hourglass™ technology has been confirmed by Blitzdirect.com, positioning the product as a leader in cannabis topical delivery. CEO Bradley Yourist emphasized the significance of this collaboration for expanding their market reach.

Grapefruit USA, Inc. (OTCQB: GPFT) has launched the world's first patented time-release, hemp-based CBD topical cream utilizing proprietary Hourglass™ technology. This innovative cream features nano-sized CBD particles for superior bioavailability and absorption. It offers sustained relief for 8-10 hours and is third-party lab tested for safety and efficacy. The Hourglass™ CBD Delivery Cream is priced at $75 per jar but is available for a limited time at $49.99. The product is designed for deep skin penetration and effective CBD delivery, making it a significant advancement in cannabinoid topical applications.

Grapefruit USA, Inc. (OTCQB: GPFT) clarifies recent executive stock sales, emphasizing that executives do not receive salaries and are compensated in common stock to align their interests with shareholders. Sales are conducted under a 10b5 Sales Plan, ensuring compliance with SEC rules and preventing insider trading concerns. This strategy helps preserve cash flow for growth-focused investments. The company remains committed to transparency and long-term success, stating that all stock transactions are publicly disclosed.

Grapefruit USA, Inc. (OTCQB: GPFT) has announced a formal collaboration with 6PAK Solutions and Medz Cannabis to launch its Hourglass™ Time Release THC+CBD Delivery Topical Relief Cream across Canada. This alliance will facilitate the filing of a Notice of New Cannabis Product (NNCP) with Health Canada, targeting a launch in Q2 2022. Grapefruit holds exclusive rights to the patented Z-Pod Xerogel technology, allowing it to create a unique delivery system that offers a healthier alternative to traditional cannabis consumption methods. CEO Bradley Yourist emphasizes the importance of regulatory compliance in this venture.